Integration Of Proteomic Aging Clocks In A Phase 2A Clinical Trial Supports Simultaneous Geroprotective Assessment
For a long time, evaluating whether a new medicine could slow down aging in humans was a huge challenge because aging itself takes decades to observe. Traditional clinical trials are designed to measure specific disease improvements, not the broader effects on the aging process. This new research introduces a groundbreaking approach to tackle this problem by using “aging clocks” in early-stage drug trials.
Imagine your body has an internal clock that reflects your biological age, which can be different from your chronological age. These “proteomic aging clocks” are sophisticated tools that analyze the patterns of thousands of proteins in your blood. Proteins are the workhorses of your cells, and their levels change dynamically with health, disease, and age, making them excellent indicators of biological shifts.
In this study, researchers applied six different proteomic aging clocks to blood samples from patients participating in a phase 2a clinical trial. This trial was testing a drug called rentosertib for idiopathic pulmonary fibrosis, a severe age-related lung disease. The exciting finding was that all six clocks consistently indicated a “younger” biological age in patients who received the drug compared to those on a placebo.
This work is a significant step forward because it suggests that we can now design clinical trials to not only see if a drug treats a specific disease but also if it has a broader impact on the aging process. While the study was small and short-term, and it’s still challenging to completely separate the drug’s effect on the disease from its potential anti-aging effects, it paves the way for a new era of drug development where medicines could be evaluated for their ability to promote healthier, longer lives.
Source: link to paper